Pratensein

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Pratensein 作为 HepG2 细胞中 B 型 I 型清道夫受体的新型转录上调剂。

Pratensein as a novel transcriptional up-regulator of scavenger receptor class B type I in HepG2 cells.

——

Pratensein significantly attenuates neuronal degeneration and apoptosis in hippocampus. The over-expression in IL-1β and TNF-α as well as the extensive astrogliosis and microgliosis in hippocampus induced by Aβ1-42 are significantly reduced following administration of Pratensein. Pratensein treatment significantly suppresses the activation of NF-κB in hippocampus. Pratensein is able to increase the levels of synaptophysin and brain-derived neurotrophic factor (BDNF). Pratensein (20 mg/kg; p.o.; once daily for 3 weeks) ameliorates learning and memory deficits in Aβ1-42 rat model of Alzheimer’s disease. Animal Model:Male 10-week old Wistar rats Dosage:20 mg/kg Administration:P.o.; once daily for 3 weeksResult:The spatial learning and memory ability of rats was improved.

——

Others

Other Targets

Others

——

——

2284-31-3

300.3

C16H12O6

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (166.52 mM)

COC1=C(C=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O)O

——

(-20℃)

With Ice Pack

≥ 2 years